First WHO Global Ministerial Conference
Ending TB in the Sustainable Development Era: A Multisectoral Response
Moscow, Russian Federation, 16-17 November 2017
Blueprint for EECA countries, first edition
HIV testing services
Policy Brief
November 2018
WHO/CDS/HIV/18.48
16-17 November 2017,
Hotel Djeugua, Yaoundé, Cameroon
Meeting Report December 2017
Meeting Report
27–30 June 2017 Manila, Philippines
Meeting Report
Bangkok, Thailand 8-11 August 2016
This Poster is available in English, French, Spanish, Russian, Chinese, Portuguese, Hausa and Arabic
Updated March 2018 | Accessed Online March 2018
The 2016-2017 Biennial report presents an overview of WHO Namibia's main achievements and challenges and highlights its vision for the next five years.
It provides insight into WHO’s work that aims to improve the health of the people of the United Republic of Tanzania in collaboration with key stakeholders.
Accessed online July 2018
An evaluation of WFP’s operation. Evaluation Report
The Protracted Relief and Recovery Operation (PRRO) main components include: relief assistance; food assistance for assets (FFA); nutrition support to women, children and HIV/TB patients; school feeding (SF) and capacity building. The evalua...tion scope covers the design phase and all activities up to this evaluation (January 2013-September 2016). Since the PRRO was extended through December 2017, the purpose is not as a final evaluation, but to provide results on achievements that can inform current and future operations
more
WHO recommends replacing western blotting and line immunoassays with simpler tests in HIV testing services. These simpler tests include rapid diagnostic tests (RDTs) that can be used at the point-of-care, and enzyme immunoassays (EIAs).
These tests get results to the client faster, produce accura...te results more often, cost less, can be performed by various cadres of health providers, and can thus facilitate greater access and uptake of HIV testing services among those who need it most.
more
The reports bring together the latest findings and conclusions about the state of resistance to artemisinins and artemisinin-based combination therapy (ACT), summarize WHO’s current policy and treatment recommendations, and highlight areas of concern.